Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium

Core Insights - Avacta Therapeutics has developed the first dual-payload peptide drug conjugate (PDC) platform, enhancing its position in oncology combination therapy innovation [1][5][6] - The upcoming presentation at the 2025 AACR-NCI-EORTC International Conference will showcase in vitro proof of mechanism data for this novel platform [2][7] Company Overview - Avacta is a clinical stage biopharmaceutical company focused on developing the pre|CISION platform, which aims to improve drug delivery in oncology by concentrating drugs directly in tumors [11][12] - The pre|CISION technology utilizes a cleavable peptide that releases the active drug only within the tumor environment, minimizing systemic toxicity [12] Technology Development - The dual-payload PDC platform allows for the simultaneous delivery of two complementary drugs targeting cancer, representing a significant advancement in the pre|CISION technology [2][4] - This innovation builds on the existing FAP-EXd (AVA6103) program, which successfully implemented a sustained release delivery mechanism [6] Clinical Implications - The dual payload approach aims to enhance treatment efficacy by targeting both the tumor and known resistance mechanisms in a single therapeutic agent [6][12] - The technology is designed to address highly-resistant cancers, potentially expanding treatment options for patients [6][12]